During the COVID-19 pandemic, home treatment for conditions such as Fabry, Gaucher or Hunter became important because it is easier for people to stick to their treatment if medicines that need to be given as infusion (called intravenous or IV treatment) can be given at home or somewhere close to home. Additionally, many of the hospitals that provide infusions are centralized in Mexico.

The main aim of the study is to find out whether people with Fabry, Gaucher or Hunter condition are more likely to continue and follow their treatment properly (called 'treatment adherence') when they receive it at home compared to when they receive it at a hospital. Other aims are to understand the factors that can influence treatment adherence, to learn about any regional differences in Mexico and to understand any medical problems with either treatment (home or hospital).

No treatment will be given during this study. Only already existing data will be reviewed during this study.

Inclusion Criteria

• Participants who met the inclusion criteria of the "Modular infusion" program

  • Confirmed diagnosis of Fabry disease, Gaucher disease, or Hunter syndrome
  • Confirmatory diagnostic test
  • Referral to the PSP from the treating physician
  • Original PSP informed consent and
  • Privacy notice signed

• Participants who met the inclusion criteria of the "Hospital infusion" program

  • Confirmed diagnosis of Fabry disease, Gaucher disease, or Hunter syndrome
  • Confirmatory diagnostic test
  • Referral to the PSP from the treating physician
  • Original PSP informed consent and
  • Privacy notice signed

• Agreement that their anonymized information will be used for research purposes

Exclusion Criteria

• Participants who do not agree or withdraw his/her explicit consent for research purposes may have the right to withdraw; however, once their data has been integrated into the database, it is no longer identifiable by any participant in the research team.
• Discontinuation of Participants

Pediatric and adult participants of all ages diagnosed with lysosomal diseases (Fabry disease, Gaucher disease, or Hunter syndrome) who are enrolled in the PSP and have consented to the use of their anonymized data for research purposes will be included in this study, regardless of whether they receive modular or hospital-based infusions.

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.